Posted On: 05/10/2015 4:22:14 PM
Post# of 145324
$MDXG Rapidly Rising Revenue Could Soar +200%
This is a very risky play on a company with valuations that are not very good; however, the gambit is that this is a rapidly growing company in the early stages of its growth phase.
Revenue growth over the last 4 years has been awesome. In 2011, revenue was $7.8 million. In 2014, revenue had grown to $118.2 million. That’s more than a +1,500% increase in revenue over the last 4 years.
On April 27, 2015, MiMedx announced first quarter results that were excellent from a growth point of view.
Highlights from the first quarter 2015 report:
Q1 2015 Wound Care sales grows 103% over Q1 2014
Q1 2015 revenue of $40.8 million increases 108% over Q1 2014
Q1 2015 Surgical, Sports Medicine/Orthopedic revenue increases 125% over Q1 2014
Q1 2015 is 14th consecutive quarter of meeting or exceeding revenue guidance
Adjusted EBITDA of $8.8 million represents a 343% improvement over Q1 2014
Quarterly net income of $4.1 million or $0.04 per diluted share vs a net loss of $900,000 or $0.01 per diluted share in Q1 2014
Q1 2015 Cash Flow from Operating Activities of $4.2 million as compared to a negative $1.6 million in Q1 2014
Company increases full year guidance range from $175-$190 million to $180-$190 million
Significant progress made during quarter in gaining coverage from commercial as well as Medicaid payers
Company signs new building lease adding approximately 25,000 sq. ft. of space in support of planned growth
MiMedx stock is in a giant Symmetrical Triangle pattern. The stock has been pulling back and has yet to trigger a Parabolic SAR buy signal:
Source: MiMedx Stock Could Soar +200%
This is a very risky play on a company with valuations that are not very good; however, the gambit is that this is a rapidly growing company in the early stages of its growth phase.
Revenue growth over the last 4 years has been awesome. In 2011, revenue was $7.8 million. In 2014, revenue had grown to $118.2 million. That’s more than a +1,500% increase in revenue over the last 4 years.
On April 27, 2015, MiMedx announced first quarter results that were excellent from a growth point of view.
Highlights from the first quarter 2015 report:
Q1 2015 Wound Care sales grows 103% over Q1 2014
Q1 2015 revenue of $40.8 million increases 108% over Q1 2014
Q1 2015 Surgical, Sports Medicine/Orthopedic revenue increases 125% over Q1 2014
Q1 2015 is 14th consecutive quarter of meeting or exceeding revenue guidance
Adjusted EBITDA of $8.8 million represents a 343% improvement over Q1 2014
Quarterly net income of $4.1 million or $0.04 per diluted share vs a net loss of $900,000 or $0.01 per diluted share in Q1 2014
Q1 2015 Cash Flow from Operating Activities of $4.2 million as compared to a negative $1.6 million in Q1 2014
Company increases full year guidance range from $175-$190 million to $180-$190 million
Significant progress made during quarter in gaining coverage from commercial as well as Medicaid payers
Company signs new building lease adding approximately 25,000 sq. ft. of space in support of planned growth
MiMedx stock is in a giant Symmetrical Triangle pattern. The stock has been pulling back and has yet to trigger a Parabolic SAR buy signal:
Source: MiMedx Stock Could Soar +200%
(0)
(0)
